RNU6-232P

Across TCGA pan-cancer cohorts, RNU6-232P RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated RNU6-232P data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RNU6-232P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-232P expression acts as an unfavorable survival marker.

STAD, ESCA, and LUAD are the cancer types where RNU6-232P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	All	0.129	0.539	<.001	36	view →
ESCA	DFS	Tertile	II,III,IV	0.254	0.535	.010	36	view →
LUAD	DFS	Tertile	II,III,IV	0.178	0.721	.008	18	view →
BRCA	DFS	Tertile	III,IV	0.141	0.796	<.001	18	view →
LIHC	OS	Tertile	All	0.183	0.690	.003	18	view →
KIRC	OS	Tertile	All	0.628	0.808	.045	12	view →
GBM	OS	Tertile	All	0.121	0.415	.042	9	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RNU6-232P–STAD (DFS)

Open the STAD breakdown →